M
Matthias Ludwig
Researcher at Bayer
Publications - 1
Citations - 107
Matthias Ludwig is an academic researcher from Bayer. The author has contributed to research in topics: Ataxia telangiectasia and Rad3 related & Ataxia-telangiectasia. The author has an hindex of 1, co-authored 1 publications receiving 26 citations.
Papers
More filters
Journal ArticleDOI
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Timothy A. Yap,David S.P. Tan,Angelika Terbuch,Angelika Terbuch,Reece Caldwell,Christina Guo,Boon Cher Goh,Valerie Heong,Noor R. Md. Haris,Saira Bashir,Yvette Drew,David S. Hong,Funda Meric-Bernstam,Gary Wilkinson,Joseph Hreiki,Antje Margret Wengner,Friedhelm Bladt,Andreas Schlicker,Matthias Ludwig,Yinghui Zhou,Li Liu,Sonal Bordia,Ruth Plummer,Eleni Lagkadinou,Johann S. de Bono +24 more
TL;DR: The dose-escalation portion of the phase I first-in-human trial of oral ATR inhibitor BAY 1895344 intermittently dosed 5-80 mg twice daily (BID) in 21 patients with advanced solid tumors is reported, finding it well tolerated with antitumor activity against cancers with certain DDR defects, including ATM loss.